Melanoma is a type of cancer that starts in skin cells that give skin its color. Melanoma has the potential to spread through the dermis to nearby tissues and other parts of the body. Melanoma can also form in the genitalia, mouth, nose, eyes, or rarely, in the internal organs. The deeper a melanoma grows into the dermis, the higher the risk of spreading through lymph vessels or blood vessels. According to the World Health Organization, a 10% ozone depletion is likely to result in an additional 300,000 non-melanoma and 4,500 melanoma cases. Approximately, 287,723 people are expected to develop melanoma by the end of 2018, with Europe and North America representing over 50.1% and 24.8% of the new cases respectively. Such high proportions of incident cases highlight an increased need for melanoma drugs in these regions over the forecast period.
The global Melanoma Treatment market was valued at $ XX Mn in 2018 and is forecast to grow at a strong XX% CAGR between 2018 and 2026, resulting in 2026 global sales of $ XX. The market is driven by due to robust medical research, high prevalence and changing the environmental landscape. However, the lack of comparative trials between new technologies is restraining market growth. Moreover, the development of next-generation therapies is providing ample opportunities for the market.
Melanoma Treatment depending on the type, Ocular Melanoma segment is expected to account for the largest share of the Melanoma Treatment market. Ocular melanoma is the most common cancer of the eye, with approximately 2,000 cases diagnosed annually.
The global Melanoma Treatment in the Healthcare market is segmented on the basis of therapy, type, and region.
Based on the Therapy: Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy, Surgery, and Pharmacological Treatment.
Based on the Type: Mucosal Melanoma and Ocular Melanoma.
Based on the region: North America, Asia-Pacific, Europe, and LAMEA. Among that North America held the largest share of the market owing to the rising incidence of melanoma and other skin cancers in the region. According to the CDC, over 87,100 people were affected by melanoma in 2017. As per the American Cancer Society, this number is expected to go up to 93,450 cases in 2021. These statistics highlight the need for drugs that help in the management of melanoma over the coming years.
The report covers in-depth analysis of Global Melanoma Treatment in the Healthcare Market. The report assesses the market products pipeline by stage of development (early development, pre-clinical, clinical and in approval), by Type (Mucosal Melanoma, Ocular Melanoma, and Cutaneous Melanoma). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement, patent, and regulatory designations.
The report includes in-depth company profiles of key players in Global Melanoma Treatment in the Healthcare Market. The company profile includes key information on the overview, financial highlights, product portfolio, business strategies, and key recent developments.
The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.
Data Collation (Primary & Secondary)
In-house Estimation (Based on proprietary databases and Models)
Market-related information is assembled from both primary and secondary sources.
Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others.
Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained.